Next-generation KRAS inhibitor divarasib extends survival in advanced lung cancer
A Phase 3 trial found the next-generation KRAS G12C inhibitor divarasib extended median overall survival to 17.7 months versus 12 ...
Tag: Krascendo 1
POPULAR NEWS
-
Microbial Sources and Stress Shape the Hidden Endophytes of an Invasive Plant
-
Firebreaks Leave Lasting Scars in Grasslands While Wildfire Heals Fast
-
ZNF207 shields glutamine transporter ASCT2 from degradation to fuel liver cancer growth
-
Systematic review maps sustainability tensions in offshore wind development